Oxford Cannabinoid Technologies Holdings PLC Clarissa Sowemimo-Coker tells Proactive's Stephen Gunnion that Medicines and Healthcare products Regulatory Agency (MHRA) approval of a phase 1 trial for its lead pain relief drug candidate, OCT461201, is a significant milestone for the company. Sowemimo-Coker said recruitment for the trial has already begun, with completion expected in the third quarter of 2023.
The drug targets chemotherapy-induced peripheral neuropathy (CIPN) and has the potential for other indications like irritable bowel syndrome (IBS) and other neuropathy. The phase 1 trial focuses on safety and will pave the way for phase 2 trials in other indications, she added.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
